Chemical Novelty Is Not Pharmacological Novelty When Natural Product Discovery Prioritizes Unusual Structures Without Demonstrating New Mechanisms or Therapeutic Functions

Download PDF

Natural product discovery often treats unusual molecular architecture as an intrinsically high-value signal, because rare scaffolds can expand explored chemical space and expose medicinal chemists to combinations of shape, stereochemistry, functionality, and biosynthetic logic that are uncommon in conventional libraries. The difficulty is not that chemical novelty lacks value, but that it is frequently allowed to stand in for stronger claims about target, mechanism, pathway, phenotype, or therapeutic function. This theoretical perspective argues that such claims belong to different evidentiary levels. Chemical novelty concerns how a molecule differs from reference chemistry, whereas pharmacological novelty concerns whether it produces a meaningfully different biological interaction, mechanism, network consequence, or therapeutically relevant function. A multidimensional novelty framework is therefore proposed in which structural difference is treated as one discovery attribute rather than as a surrogate for downstream biological difference. The analysis distinguishes scaffold and substructure novelty from target novelty, target engagement from causal mechanism, multi-target activity from network-level novelty, and phenotypic difference from therapeutic functional difference. It also emphasizes asymmetric cases in which new chemistry reaches familiar pharmacology and familiar chemistry remains pharmacologically valuable. The framework is intended to improve claim discipline and portfolio prioritization, not to supply a validated scoring system or universal threshold. Its applicability depends on representation choices, assay context, target evidence, biological model relevance, exposure, and the predictive validity of evidence used for downstream decisions.